NZ500288A - Gastric-retained pharmaceutical composition comprising benzamide as the active principle and a carbon dioxide generating system - Google Patents

Gastric-retained pharmaceutical composition comprising benzamide as the active principle and a carbon dioxide generating system

Info

Publication number
NZ500288A
NZ500288A NZ500288A NZ50028898A NZ500288A NZ 500288 A NZ500288 A NZ 500288A NZ 500288 A NZ500288 A NZ 500288A NZ 50028898 A NZ50028898 A NZ 50028898A NZ 500288 A NZ500288 A NZ 500288A
Authority
NZ
New Zealand
Prior art keywords
carbon dioxide
benzamide
gastric
pharmaceutical composition
active principle
Prior art date
Application number
NZ500288A
Inventor
Jerome Besse
Original Assignee
Sanofi Synthelabo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Synthelabo filed Critical Sanofi Synthelabo
Publication of NZ500288A publication Critical patent/NZ500288A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Anesthesiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A gastric-retained pharmaceutical composition, characterised in that it comprises: (a) an active principle consisting of a benzamide such as tiapride or amisupride, or one of its salts; (b) a system for generating carbon dioxide, comprising a carbon dioxide generator agent such as calcium carbonate or sodium bicarbonate, and a monocarboxylic acid or a polycarboxylic acid ; and (c) means for partially retaining the carbon dioxide generated by the carbon dioxide generating means, such as a hydrophilic polymer.
NZ500288A 1997-04-18 1998-04-15 Gastric-retained pharmaceutical composition comprising benzamide as the active principle and a carbon dioxide generating system NZ500288A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9704803A FR2762213B1 (en) 1997-04-18 1997-04-18 PHARMACEUTICAL COMPOSITION WITH GASTRIC RETENTION
PCT/FR1998/000755 WO1998047506A1 (en) 1997-04-18 1998-04-15 Gastric-retained pharmaceutical composition

Publications (1)

Publication Number Publication Date
NZ500288A true NZ500288A (en) 2001-03-30

Family

ID=9506077

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ500288A NZ500288A (en) 1997-04-18 1998-04-15 Gastric-retained pharmaceutical composition comprising benzamide as the active principle and a carbon dioxide generating system

Country Status (19)

Country Link
EP (1) EP0983065A1 (en)
JP (1) JP2001523241A (en)
KR (1) KR20010006353A (en)
CN (1) CN1252720A (en)
AR (1) AR015586A1 (en)
AU (1) AU737634B2 (en)
CA (1) CA2286081A1 (en)
FR (1) FR2762213B1 (en)
HU (1) HUP0002455A3 (en)
IL (1) IL131995A0 (en)
JO (1) JO2017B1 (en)
MA (1) MA26482A1 (en)
NO (1) NO995039L (en)
NZ (1) NZ500288A (en)
PE (1) PE68199A1 (en)
PL (1) PL336273A1 (en)
TN (1) TNSN98049A1 (en)
WO (1) WO1998047506A1 (en)
ZA (1) ZA983258B (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6169094B1 (en) * 1998-07-14 2001-01-02 Sanofi-Synthelabo Compositions of (S) (-)-amisulpride
FR2784583B1 (en) 1998-10-16 2002-01-25 Synthelabo PHARMACEUTICAL COMPOSITION WITH GASTRIC RESIDENCE AND CONTROLLED RELEASE
FR2790388B1 (en) * 1999-03-04 2001-04-13 Synthelabo PHARMACEUTICAL COMPOSITIONS COMPRISING A BENZAMIDE AND AT LEAST ONE ABSORPTION PROMOTER
EP1245227A1 (en) 2001-03-31 2002-10-02 Jagotec Ag A pharmaceutical tablet system that floats in the stomach for programmed release of active substance and process of producing buoyant material contained in same
WO2009157711A2 (en) * 2008-06-24 2009-12-30 Park Eun-Seok Gastro-retentive porous tablet and method for preparing same
FR2949061B1 (en) * 2009-08-12 2013-04-19 Debregeas Et Associes Pharma FLOATING MICROGRANULES
EP2719376B1 (en) 2012-10-12 2015-03-04 Omya International AG Gastroretentive drug formulation and delivery systems and their method of preparation using functionalized calcium carbonate
KR20200110317A (en) 2017-12-05 2020-09-23 선오비온 파마슈티컬스 인코포레이티드 Crystal form and method for preparing the same
KR20200110648A (en) 2017-12-05 2020-09-24 선오비온 파마슈티컬스 인코포레이티드 Non-racemic mixtures and uses thereof
JP7044649B2 (en) * 2018-06-28 2022-03-30 株式会社ファンケル Intragastric floating tablets
AU2020286441A1 (en) 2019-06-04 2022-01-06 Sunovion Pharmaceuticals Inc. Modified release formulations and uses thereof
WO2023214018A1 (en) 2022-05-06 2023-11-09 Galenix Innovations Gastro-retentive swellable sustained release composition

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2415099A1 (en) * 1978-01-20 1979-08-17 Ile De France NEW DERIVATIVES OF 4-AMINO-5-ALKYLSULFONYL ORTHO-ANISAMIDES, THEIR METHODS OF PREPARATION AND THEIR APPLICATION AS PSYCHOTROPES
FR2554718B1 (en) * 1983-11-14 1986-04-04 Ethypharm Sa NEW ORAL SULPIRIDE FORMS FOR SULPIRIDE
FR2556964A1 (en) * 1983-12-23 1985-06-28 Ile De France NEW GALENIC FORMS OF SULPIRIDE USED ORALALLY
JPS62178518A (en) * 1986-01-30 1987-08-05 Toho Yakuhin Kogyo Kk Novel long-acting sulpiride tablet
JPH0776172B2 (en) * 1986-04-16 1995-08-16 藤沢薬品工業株式会社 Matrice locks
CA2039742A1 (en) * 1990-04-23 1991-10-24 Andrew B. Dennis Tablet composition and method for problem pharmaceutical materials

Also Published As

Publication number Publication date
EP0983065A1 (en) 2000-03-08
AU737634B2 (en) 2001-08-23
WO1998047506A1 (en) 1998-10-29
FR2762213B1 (en) 1999-05-14
JP2001523241A (en) 2001-11-20
ZA983258B (en) 1998-10-19
KR20010006353A (en) 2001-01-26
HUP0002455A2 (en) 2000-12-28
JO2017B1 (en) 1999-05-15
NO995039D0 (en) 1999-10-15
TNSN98049A1 (en) 2005-03-15
AR015586A1 (en) 2001-05-16
AU7341698A (en) 1998-11-13
MA26482A1 (en) 2004-12-20
CN1252720A (en) 2000-05-10
PL336273A1 (en) 2000-06-19
IL131995A0 (en) 2001-03-19
FR2762213A1 (en) 1998-10-23
HUP0002455A3 (en) 2001-01-29
NO995039L (en) 1999-12-17
PE68199A1 (en) 1999-07-15
CA2286081A1 (en) 1998-10-29

Similar Documents

Publication Publication Date Title
NZ500288A (en) Gastric-retained pharmaceutical composition comprising benzamide as the active principle and a carbon dioxide generating system
SE8902288L (en) PHARMACEUTICAL COMPOSITION
IL114449A0 (en) Multiple unit tableted dosage form
UA66847C2 (en) Solid rapidly decomposing fizzy dosage form of selegiline and method for its production
BR9815064A (en) Detergent tablet
EP0221732A3 (en) Sustained release tablets
ZA947337B (en) Use of angiotensin II analogs in tissue repair
DK0730465T3 (en) Use of angiotensin III and analogues thereof for tissue repair
MXPA97002401A (en) Antiinflammatory agent for external use.
BR9814217A (en) Super absorbent gels based on poly (vinylguanidine)
FI974618A0 (en) Divalent and trivalent small molecule selectin inhibitors
MX9702456A (en) Liquid antacid compositions containing calcium carbonate and possibly simethicone as active compounds and monobasic potassium phosphate and potassium bicarbonate as buffer.
GR3019514T3 (en) Pharmaceutical preparation for the treatment of prolonged coagulation time
DE69716586D1 (en) BUFFERED ORTHOESTER POLYMERS CONTAINING MEDICINAL PRODUCTS
ATE307497T1 (en) PHARMACEUTICAL COMPOSITION
PL346764A1 (en) New oral formulation for 5-ht4
ES2174293T3 (en) PHARMACEUTICAL MICROSPHERES OF VALPROIC ACID FOR ORAL ADMINISTRATION.
HUP9903804A1 (en) Antimycotic gel with high active substance release
DK0497724T3 (en) Means for the disintegration of gallstones
AU2794289A (en) Paging terminal apparatus with message storage and retransmission capability and method therefor
AU2651288A (en) All-in-one boiler water treatment composition
AU4950296A (en) Use of a pyruvate dehydrogenase activator for the treatment of ischaemia in limbs
GR77250B (en)
FR2764281B1 (en) PROCESS FOR THE PREPARATION OF COMPOSITIONS ESSENTIALLY COMPRISING AN ABSORBENT ANHYDROUS ALKALINE METAL CARBONATE
AR034993A1 (en) MEDICINAL PRODUCT FOR THE PREVENTION OF CLINICAL AND SUBCLINICAL ACIDOSIS IN POLICAVITARY AND / OR RUMINANT ANIMALS

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)